retatrutide lancet New GLP-3 drug significantly slashes both weight and blood sugar levels in Phase III trial ADA 2026: Retatrutide Revolution

Blood pressure improvements appear early in treatment

knownwell clinicians can also suggest alternative medications such as metformin to assist with your metabolic health postpartum

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Approval (Most Likely): FDA issues approval letter

Tirzepatide dry mouth profile Tirzepatide, marketed as Mounjaro and Zepbound, shows a reporting-odds ratio of 1.35 for dry mouth, marginally higher than semaglutide

To facilitate routine screening in clinical settings where GLP-1 RAs are typically prescribed (e.g